COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Affiliations

¹ From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. v.shaygannejad@gmail.com.

Case Reports

Mahdi Barzegar et al. Neurol Neuroimmunol Neuroinflamm. 2020.

. 2020 May 5;7(4):e753.

doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.

¹ From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
² From the Department of Neurology (M.B., O.M., R.S., V.S.), School of Medicine, Isfahan University of Medical Sciences; Isfahan Neurosciences Research Center (M.B., O.M., N.N., V.S.), Isfahan University of Medical Sciences; Acquired Immunodeficiency Research Center (F.K.), Isfahan University of Medical Sciences, Iran; and Ann Romney Center for Neurologic Diseases (A.-H.M.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. v.shaygannejad@gmail.com.

No abstract available

Figures

1. Guan W, Ni Z, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med Epub 2020 Feb 28. - PMC - PubMed
1. Luna G, Alping P, Burman J, et al. . Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2020;77:184–191. - PMC - PubMed
1. Bernheim A, Mei X, Huang M, et al. . Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology Epub 2020 Feb 20. - PMC - PubMed
1. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 2019;39:102073. - PMC - PubMed
1. Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther 2019;8:241–250. - PMC - PubMed